Abrégé

The present invention relates to use of C1Q and/or a subunit thereof as a target in the prevention and treatment of psoriasis. The C1QA/B/C gene expression in monocytes/macrophages in psoriatic skin lesions is enhanced, the content of C1Q subunit protein in the serum of psoriasis patients exhibits a significant difference before and after treatment, and the expression level of C1Q subunit protein in the serum of psoriasis patients after treatment is significantly reduced. In addition, the C1Q gene knockout can effectively reduce the expression of psoriasis-related inflammatory factors such as IFN-gamma and TNF in C1Q gene-knockout monocytes, indicating that by inhibiting the expression or function of C1Q, the immune response and inflammation level in psoriasis patients can be regulated, thus achieving effective prophylactic and therapeutic effects on psoriasis. Therefore, C1Q can be used as a biological treatment target for psoriasis to prepare a medicament for the prevention and treatment of psoriasis.

Classes IPC  ?

• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
• A61P 37/02 - Immunomodulateurs
• A61P 17/06 - Antipsoriasiques

Abrégé

Provided are a medicinal and edible homologous tea beverage for relieving summer-heat and eliminating dampness, a preparation method therefor, and use thereof. The medicinal and edible homologous tea beverage is prepared from the following starting materials in parts by weight: 3-20 parts of agastache rugosus, 2-20 parts of elsholtzia ciliata, 5-30 parts of codonopsis pilosula, and 1-15 parts of tangerine peel. The tea beverage can dispel summer-heat and relieve the exterior syndrome, resolve dampness through its aromatic properties, and regulate qi and strengthen the middle energizer, thereby ameliorating or alleviating heatstroke symptoms in subjects.

Classes IPC  ?

• A61K 36/752 - Citrus, p. ex. citron vert, orange ou citron
• A61K 36/532 - Agastache, p. ex. hysope
• A61K 36/53 - Lamiaceae ou Labiatae (famille de la menthe), p. ex. thym, romarin ou lavande
• A61K 36/344 - Codonopsis
• A23F 3/34 - Succédanés du thé, p. ex. matéExtraits ou infusions de ceux-ci
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

A traditional Chinese medicine composition for replenishing qi and enhancing immunity in children, a preparation method therefor, and use thereof. The traditional Chinese medicine composition comprises the following raw materials: 5-10 parts by weight of Codonopsis radix, 10-20 parts by weight of Ficus hirta, 10-20 parts by weight of Poria, 10-20 parts by weight of Hordei germinatus fructus, and 10-20 parts by weight of Mume fructus. Codonopsis radix, as a monarch drug, and Ficus hirta, as a minister drug, cooperate to invigorate the spleen, replenish qi, and regulate the immune function of the body. Moreover, Poria, Hordei germinatus fructus, and Mume fructus are used to invigorate the spleen, promote digestion, and nourish yin. The traditional Chinese medicine composition can ameliorate clinical symptoms in pediatric patients with recurrent respiratory tract infection.

Classes IPC  ?

• A61K 36/8998 - Hordeum (orge)
• A61K 36/344 - Codonopsis
• A61K 9/08 - Solutions
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61P 1/14 - Eupeptiques, p. ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A61P 37/04 - Immunostimulants
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 31/00 - Extraits ou préparations comestibles de champignonsLeur préparation ou leur traitement

Abrégé

A spleen-invigorating and dampness-eliminating medicinal and edible homologous composition, and a preparation method therefor and use thereof. The medicinal and edible homologous composition comprises the following raw material components in parts by mass: 3-30 parts of Codonopsis pilosula, 5-40 parts of lotus seeds, 10-40 parts of coix seeds, 10-40 parts of Gordon Euryale seeds, 1-15 parts of dried tangerine peels, and 5-30 parts of wolfberry. Aiming at individuals with spleen deficiency accompanied by dampness, whose main manifestations comprise being overweight, heaviness in the hands, feet, head, or body, bland or astringent taste in the mouth, loose or watery stools, etc., the method of syndrome differentiation and treatment in Traditional Chinese Medicine is adopted to invigorate the spleen and eliminate dampness, while also astringing the intestines to stop diarrhea. Moreover, the composition also takes into account the congenital foundation by regulating kidney yang. The composition can effectively ameliorate symptoms, such as being overweight, heaviness in the hands, feet, head, or body, bland or astringent taste in the mouth, loose or watery stools, etc., in individuals with spleen deficiency accompanied by dampness.

Classes IPC  ?

• A61K 36/8994 - Coix (Lacrimia Jobi)
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/00 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement
• A61K 36/344 - Codonopsis
• A61P 1/14 - Eupeptiques, p. ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

Classes IPC  ?

• A61K 36/37 - Celastraceae (famille du bourreau des arbres ou de la camarine), p. ex. tripterygium ou fusain
• A61K 36/282 - Artemisia, p. ex. armoise
• A61K 31/585 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes contenant des hétérocycles, p. ex. danazol, stanozolol, pancuronium ou digitogénine contenant des cycles lactone, p. ex. oxandrolone, bufaline
• A61K 31/56 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes
• A61P 17/06 - Antipsoriasiques
• A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe

Abrégé

A 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound having a structural formula as represented by formula I and the use thereof in the preparation of an anti-tumor drug. The 2-aryl-2,3,4,5-tetrahydro-1,4-epoxybenzazepine compound has good tumor cell proliferation inhibition activity against at least one among a human lung cancer cell A549, a human colon cancer cell HCT116, a human liver cancer cell HepG2, and a human breast cancer cell MCF-7.

Classes IPC  ?

• C07D 498/08 - Systèmes pontés
• A61K 31/537 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. 1,2-oxazines condensées en spiro ou formant une partie de systèmes cycliques pontés
• A61P 35/00 - Agents anticancéreux

Abrégé

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

Classes IPC  ?

• A61K 36/89 - Cyperaceae (famille de la laîche)
• A61K 36/75 - Rutaceae (famille de la rue)
• A61K 36/34 - Campanulaceae (famille de la campanule)
• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p. ex. aneth, cerfeuil, coriandre ou cumin
• A61P 11/14 - Antitussifs
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

Classes IPC  ?

• A61K 36/9068 - Zingiber, p. ex. gingembre
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61P 11/14 - Antitussifs
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 11/10 - Expectorants

Abrégé

Provided are a traditional Chinese medicine composition for tonifying Qi, activating blood and detoxificating and use thereof. The composition is prepared from the following ingredients: 10-30 parts of sun-dried ginseng, 6-30 parts of pseudo-ginseng, and 3-15 parts of Rheum officinale. The traditional Chinese medicine composition can ameliorate the illness state of patients suffering from sepsis secondary to pulmonary infection, and the oxygen saturation of the patients is improved by means of bowel-relaxing and anti-inflammation effects, thus shortening the mechanical ventilation time of the patients.

Classes IPC  ?

• A61K 36/708 - Rheum (rhubarbe)
• A61K 36/258 - Panax (ginseng)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/04 - Agents antibactériens

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

• A61K 31/365 - Lactones
• A61P 35/00 - Agents anticancéreux
• C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes

Abrégé

A traditional Chinese medicine for the treatment of diabetic nephropathy, comprising the following raw materials in parts by weight: 9-30 parts of radix astragali, 6-15 parts of semen cuscutae, 5-10 parts of peach kernel, 3-10 parts of rhizoma atractylodis, 3-10 parts of dried tangerine peel, 15-30 parts of centella asiatica, and 3-10 parts of cordyceps cicadae.

Classes IPC  ?

• A61K 36/752 - Citrus, p. ex. citron vert, orange ou citron
• A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
• A61P 37/02 - Immunomodulateurs
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

The present invention belongs to the field of traditional Chinese medicine, and in particular, to a composition for preventing rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition for preventing rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 15-60 parts of raw Semen Coicis, 5-30 parts of Radix Angelicae Sinensis, 5-30 parts of Radix Paeoniae Alba, 1-15 parts of Herba Ephedrae, 5-30 parts of Ramulus Cinnamomi, 5-30 parts of Radix Glycyrrhizae Praeparata, 5-30 parts of Rhizoma Atractylodis, and 10-60 parts of Radix Astragali. Proved by a CIA rat model experiment, the composition for preventing rheumatoid arthritis of the present invention can obviously alleviate the joint swelling degree of a CIA rat, X ray shows that bone destruction can be improved, and a pathological section shows good effects of inhibiting synovial tissue proliferation, reducing inflammatory cell infiltration, and delaying bone and cartilage destruction, thereby achieving the effects of symptom improvement, bone protection and anti-inflammatory for the CIA rat.

Classes IPC  ?

• A61K 36/8994 - Coix (Lacrimia Jobi)
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

A composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition is made from the following raw material components in parts by mass: 10-40 parts of Radix Salviae Miltiorrhizae, 15-120 parts of Rhizoma Dioscoreae Nipponicae, 15-60 parts of Radix Astragali, 5-30 parts of Radix Paeoniae Alba, 3-15 parts of Ephedra, 3-15 parts of Radix Aconiti Laterailis Prepareata, 5-30 parts of Morinda Officinalis, and 5-30 parts of honey-fried licorice root. By means of clinical tests, it is proven that said composition can alleviate the symptoms of articulation swelling and suffered by patients, control the level of inflammation and disease progression, and has potential bone protection effects.

Classes IPC  ?

• A61K 36/8945 - Dioscorea, p. ex. igname, Dioscorea opposita ou Dioscorea alata
• A61K 36/746 - Morinda
• A61K 36/714 - Aconitum (aconit)
• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p. ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
• A61K 36/537 - Salvia (sauge)
• A61K 36/484 - Glycyrrhiza (réglisse)
• A61K 36/481 - Astragalus (astragalus cicer)
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget

Abrégé

The present invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor and an application thereof. The composition for preventing and/or treating rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 5-30 parts Notopterygium root, 5-45 parts kadsura pepper stem, 3-20 parts of prepared aconite root, 5-30 parts of Gentiana macrophylla, 5-30 parts of ramulus mori, 5-30 parts of Angelica sinensis, 5-20 parts of Ligusticum wallichii, 3-15 parts of Costustoot, and 3-30 parts of Radix glycyrrhizae preparata. According to clinical trials, the composition for preventing and/or treating rheumatoid arthritis of the present invention can improve the symptoms of joint swelling and pain in patients, control inflammation levels and disease progression, and has potential bone protection effects.

Classes IPC  ?

• A61K 36/714 - Aconitum (aconit)
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed in the present invention is an application of a glutaminase inhibitor in preparation of a drug for treating psoriasis. According to the present invention, in-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, comprising remarkably reducing a Baker score of a skin lesion, effectively reducing an epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67 positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing a drug for treating psoriasis.

Classes IPC  ?

• A61K 31/42 - Oxazoles
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
• A61K 31/433 - Thiadiazoles
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 17/06 - Antipsoriasiques

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in the preparation of anti-cancer drugs. The triptolide acrylate of the present invention and pharmaceutically acceptable salts thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments prove that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting cancer cell metastasis. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

• C07D 493/22 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient au moins quatre hétérocycles
• C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes
• A61K 31/365 - Lactones
• A61P 35/00 - Agents anticancéreux

Abrégé

Applications of psoralen in preparing an Nrf2 inhibitor, a medicament for Nrf2 inhibition-related diseases, and an anticancer medicament. Psoralen reduces the level of Nrf2 protein expression, reduces the antioxidative stress ability of human non-small cell lung carcinoma A549 cells, and increases the proapoptotic effects of chemotherapeutic medicament cisplatin with respect to A549. Psoralen has no significant impact on animal liver and kidneys when used as a medicament.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61K 33/243 - PlatineSes composés
• A61P 35/00 - Agents anticancéreux